Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
肿瘤
/
蛋白酶
肿瘤干细胞 PPARs Wnt
/ MMP / Marimastat

马立马司他 /Marimastat {[allProObj[0].p_purity_real_show]}

货号：A573351 同义名： BB2516;TA2516

Marimastat is a competitive and broad-spectrum MMP inhibitor with IC50 values of 3, 5, 6, 9 and 13 nM for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7, respectively.

Marimastat 化学结构 CAS号：154039-60-8
Marimastat 化学结构
CAS号：154039-60-8
Marimastat 3D分子结构
CAS号：154039-60-8
Marimastat 化学结构 CAS号：154039-60-8
Marimastat 3D分子结构 CAS号：154039-60-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Marimastat 纯度/质量文件 产品仅供科研

货号：A573351 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell, 2024, 101755. Ambeed. [ A399663 ]
• EMBO J., 2024. Ambeed. [ A295334 ]
• JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]
• JMC, 2024. Ambeed. [ A210558 , A1518164 ]
• Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]
更多 >
产品名称 MMP ↓ 其他靶点 纯度
Marimastat +++

MMP-14, IC50: 3 nM

MMP-7, IC50: 16 nM

 		98%
Ilomastat ++++

MMP-2, Ki: 0.1 nM

MMP-26, Ki: 0.36 nM

 		99%+
SB-3CT +

MMP-2, Ki: 13.9 nM

MMP-9, Ki: 600 nM

 		99%+
Doxycycline ✔ 98%
Batimastat +++

MMP-7, IC50: 4 nM

MMP-1, IC50: 3 nM

 		99%+
Nobiletin ✔ 98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Marimastat 生物活性

靶点

  • MMP

    MMP-14, IC50:3 nM

    MMP-7, IC50:16 nM
描述 Marimastat is a broad spectrum MMP inhibitor with IC50 values of 3, 5, 6, 9 and 13 nM for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 respectively[1]. Marimastat is the orally bioavailable analogue of hydroxamate peptidomimetic inhibitor batimastat[2]. Treatment with 10μM marimastat could inhibit elastin degradation and active MMP-2 production with aortic organ culture[3]. Marimastat at concentration of 50μg/ml could significantly reduce the invasion of osteosarcoma cells by 30-60%, including U2OS, OHS, and SaOS cells, but not KPDX cells[4]. Daily administration of marimastat at concentration of 27 mg/kg for 2 weeks by subcutaneously-inoculating mini-osmotic pumps could inhibit peritoneal dissemination of human gastric cancer cells through inhibition of tumor angiogenesis in SCID mice injected with human gastric cancer cells[5]. Marimastat also works as an inhibitor of TACE (tumor necrosis factor-α converting enzyme). An oral dose of 200mg/kg marimastat almost completely inhibited LPS-induced soluble TNF-α production, but only slightly delayed LPS lethality in mice[6].
作用机制 Marimastat is a hydroxamate peptidomimetic compound which can bind covalently to the zinc atom at the MMP-active site.[2]

Marimastat 动物研究

Dose Mice: 8.7 mg/kg[7] (subcutaneous osmotic pump), 18 mg/kg[8] (s.c.); 100 mg/kg[9] (p.o.)
Administration OMP (s.c.), p.o.

Marimastat 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00261391 Vascular Anomalies Phase 1 Completed - United States, Massachusetts ... 展开 >> Childrens Hospital Boston, Massachusetts, United States, 02115 收起 <<
NCT00002911 Lung Cancer Phase 3 Completed - -
NCT00003010 Breast Cancer Phase 3 Completed - United States, Arizona ... 展开 >> CCOP - Scottsdale Oncology Program Scottsdale, Arizona, United States, 85259-5404 United States, Illinois Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States, 60611 CCOP - Carle Cancer Center Urbana, Illinois, United States, 61801 United States, Iowa CCOP - Cedar Rapids Oncology Project Cedar Rapids, Iowa, United States, 52403-1206 CCOP - Iowa Oncology Research Association Des Moines, Iowa, United States, 50309-1016 Siouxland Hematology-Oncology Sioux City, Iowa, United States, 51101-1733 United States, Kansas CCOP - Wichita Wichita, Kansas, United States, 67214-3882 United States, Minnesota CCOP - Duluth Duluth, Minnesota, United States, 55805 Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 CentraCare Clinic Saint Cloud, Minnesota, United States, 56303 United States, Nebraska CCOP - Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68131 United States, New Jersey Trinitas Hospital - Jersey Street Campus Elizabeth, New Jersey, United States, 07201 Hunterdon Regional Cancer Center Flemington, New Jersey, United States, 08822 Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Morristown Memorial Hospital Morristown, New Jersey, United States, 07962-1956 Riverview Medical Center Red Bank, New Jersey, United States, 07701 St. Francis Medical Center Trenton, New Jersey, United States, 08629 United States, New York Albert Einstein Comprehensive Cancer Center Bronx, New York, United States, 10461 United States, North Dakota Medcenter One Health System Bismarck, North Dakota, United States, 58501 Altru Health Systems Grand Forks, North Dakota, United States, 58201 United States, Ohio CCOP - Columbus Columbus, Ohio, United States, 43206 CCOP - Toledo Community Hospital Oncology Program Toledo, Ohio, United States, 43623-3456 United States, Pennsylvania Hahnemann University Hospital Philadelphia, Pennsylvania, United States, 19102-1192 United States, South Dakota Rapid City Regional Hospital Rapid City, South Dakota, United States, 57709 CCOP - Sioux Community Cancer Consortium Sioux Falls, South Dakota, United States, 57105-1080 收起 <<

Marimastat 参考文献

[1]Rasmussen HS, McCann PP, et al. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75.

[2]Hidalgo M, Eckhardt SG, et al. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001 Feb 7;93(3):178-93.

[3]Treharne GD, Boyle JR, et al. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg. 1999 Aug;86(8):1053-8.

[4]Bjørnland K, Flatmark K, et al. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 2005 Aug;127(2):151-6. Epub 2005 Apr 14.

[5]Wada N, Otani Y, et al. Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. Clin Exp Metastasis. 2003;20(5):431-5.

[6]Tsuji F, Oki K, et al. Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis. Cytokine. 2002 Mar 21;17(6):294-300.

Marimastat 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.02mL

0.60mL

0.30mL

15.09mL

3.02mL

1.51mL

30.17mL

6.03mL

3.02mL

Marimastat 技术信息

CAS号154039-60-8
分子式C15H29N3O5
分子量 331.408
别名 BB2516;TA2516;KB-R8898
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Store in freezer, under -20°C
溶解度

DMSO: 105 mg/mL(316.83 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

Tags: Marimastat | 154039-60-8 | BB2516 | TA2516 | BB 2516 | BB-2516 | TA2516 | TA 2516 | TA-2516 | MMP Inhibitor | Metabolic Enzyme/Protease | MMP | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Marimastat 纯度/质量文件 | Marimastat 亚型比较 | Marimastat 生物活性 | Marimastat 动物研究 | Marimastat 临床数据 | Marimastat 参考文献 | Marimastat 实验方案 | Marimastat 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z